ResMed Inc. 10-Q Summary: Quarter Ended March 31, 2002
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation designing, manufacturing, and marketing devices for sleep disordered breathing. The report covers the three and nine-month periods ended March 31, 2002. The Company's principal manufacturing operations are located in Australia, with major distribution sites in the U.S., Europe, and Asia.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2002 | Nine Months Ended Mar 31, 2002 |
|---|---|---|
| Net Revenue | $52.8 million | $147.8 million |
| Gross Profit | $33.8 million | $96.4 million |
| Gross Margin | 64.0% | 65.2% |
| Operating Income | $12.6 million | $39.2 million |
| Net Income | $10.4 million | $27.7 million |
| Diluted EPS | $0.31 | $0.81 |
| Cash from Operations (9mo) | $27.2 million | |
| Cash & Equivalents (Mar 31, 2002) | $56.2 million | |
| Convertible Notes Outstanding | $146.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 24% year-over-year for the quarter and 37% for the nine-month period, driven by higher unit sales of flow generators and the acquisition of MAP Medizin-Technologie GmbH.
- Profitability: The Company reported a net income of $10.4 million for the quarter, a significant turnaround from a net loss of $10.2 million in the same period of 2001. The prior year loss included a $17.7 million write-off of in-process research and development.
- Margin Compression: Gross margins declined from 67.8% to 64.0% for the quarter due to a shift in sales mix toward domestic markets, which carry lower margins than international markets.
- Debt Reduction: The Company repurchased $34.0 million face value of convertible subordinated notes for $30.2 million, recognizing an extraordinary gain of $1.9 million (net of tax).
Outlook, Risks, and Unusual Items
- Unusual Items: The quarter included a $1.0 million donation to the ResMed Sleep Disordered Breathing Foundation. The prior year included a $17.7 million in-process R&D write-off and a $0.55 million restructuring charge, which are not present in the current period.
- Capital Expenditures: The Company is investing heavily in a new 30-acre manufacturing and R&D site in Sydney, Australia. A deposit of $2.4 million was paid in the prior quarter, with settlement of $11.3 million occurring in April 2002. Total estimated building costs are $30.0 million.
- Liquidity: Working capital increased to $162.8 million. The Company expects to meet short-term liquidity needs through cash on hand and operating cash flow.
- Risks: Key risks include foreign currency exchange fluctuations (hedged via options), reliance on single-source suppliers for components, and ongoing patent litigation against competitor Respironics. Regulatory compliance (FDA) and third-party reimbursement policies remain critical factors.
Investor Verification Checklist
- Debt Repurchase Impact: Verify the sustainability of the $1.9 million extraordinary gain from debt extinguishment and the remaining $146 million convertible note obligation.
- Margin Trends: Monitor the shift in geographic sales mix and its continued impact on gross margins, particularly as domestic sales grow.
- Capital Project Execution: Track the progress and cost overruns of the new Sydney facility, which requires significant future cash outlays ($5.7 million deferred payments due in late 2002 and 2003).
- Legal Contingencies: Review the status of the patent infringement litigation with Respironics, as adverse rulings could impact future revenue streams.
- Foreign Exchange Exposure: Assess the effectiveness of the foreign currency hedging program given the Company's significant Australian manufacturing costs and international revenue base.